Macular Disease Foundation Australia logo

    Research news

    Research News

    The latest funding round now brings MDFA’s commitment to macular disease research to $5.8 million across 35 projects since 2011.

    Read more

    Most recent

     Could a new supplement help slow AMD?

    A/Prof Gerald Liew’s second MDFA Research Grant is allowing him to investigate a potential sight-saving supplement to improve dysfunctional mitochondria and prevent age-related macular degeneration (AMD). 

    2023 Research Grant Program recipients announced

    MDFA is Australia’s largest source of research funding in the field of macular disease outside of government.

    2023 Research Grant recipient

    Spatial transcriptomics in diabetic macular ischaemia

    2023 Research Grants Program

    MDFA is Australia’s largest source of research funding in the field of macular disease outside of government

    Excellence in Research Award in honour of Richard Grills (AM)

    Composition and functionality of high-density lipoprotein in age-related macular degeneration and a high-risk disease phenotype

    2023 Research Grant Family Fund recipient

    Redefining macular disease diagnosis to improve access to emerging therapies

    2023 Research Grant Recipient

    Investigating mitochondrial dysfunction in macular degeneration – towards new treatments and biomarkers

    2023 Research Grant Family Fund recipient

    Evaluating the potential of hyperspectral imaging for detecting and monitoring geographic atrophy Accurate monitoring of

    Vabysmo® (faricimab) now available in Australia 

    Vabysmo is a new treatment for age-related macular degeneration and diabetic macular oedema and is now available on the Pharmaceutical Benefits Scheme (PBS) in Australia

    Loading...